Anti-Synthetase Syndrome clinical trials at UCSF
1 research study open to eligible people
Anti-synthetase syndrome is a condition where the immune system attacks muscles and lungs. UCSF is studying treatments like CABA-201 for people with active inflammatory myopathy. UCSF is monitoring safety, strength, breathing, and lab measures during the studies.
Showing trials for
RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy
open to eligible people ages 6-75
RESET-Myositis: Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects with Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy
San Francisco, California and other locations
Our lead scientists for Anti-Synthetase Syndrome research studies include Susan Kim, MD, MMSc.
Last updated: